Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, inrats with partial 6-OHDA or FeCl3 nigrostriatal lesions
Kp. Datla et al., Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, inrats with partial 6-OHDA or FeCl3 nigrostriatal lesions, MOVEMENT D, 16(3), 2001, pp. 424-434
In this study, we have examined the effects of chronic L-3,4-dihydroxypheny
lalanine (L-DOPA) administration on the remaining dopaminergic neurons in r
ats with 6-hydroxydopamine (6-OHDA) or buffered FeCl3 partial lesions to th
e nigrostriatal tract. L-DOPA administration increased the turnover of dopa
mine in the striatum. L-DOPA administration for 1 week produced an increase
in the level of striatal RTI-121 binding, a specific marker for dopamine u
ptake sites: on the dopaminergic nerve terminals in the striatum. However,
longer periods of L-DOPA treatment decreased the level of RTI-121 binding i
n the striatum. In the partial 6-OHDA lesion model, L-DOPA treatment had a
time-dependent effect on the number of neurons demonstrating a dopaminergic
phenotype i.e., neurons that are tyrosine hyrdoxylase (TH)immunopositive,
on the lesioned side of the brain. In the first few weeks of treatment, L-D
OPA decreased the number of TH-positive neurons but with long-term treatmen
t, i.e., 24 weeks, L-DOPA increased the number of neurons demonstrating a d
opaminergic phenotype, Even in the buffered FeCl3 infusion model, where the
levels of iron were increased, L-DOPA treatment did not have any detriment
al effects on the number of TH-positive neurons on the lesioned side of the
brain. Consequently, chronic L-DOPA treatment does not have any detrimenta
l effects to the remaining dopaminergic neurons in rats with partial lesion
s to the nigrostriatal tract, indeed in the 6-OHDA lesion model, long-term
L-DOPA may increase the number of neurons, demonstrating a dopaminergic phe
notype. (C) 2001 Movement Disorder Society.